Skip to main content

Cilastatin / Imipenem Side Effects

Medically reviewed by Drugs.com. Last updated on Mar 8, 2024.

Applies to cilastatin / imipenem: powder for solution.

Serious side effects

Along with its needed effects, cilastatin / imipenem may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking cilastatin / imipenem:

More common

  • confusion
  • convulsions (seizures)
  • dizziness
  • pain at place of injection
  • skin rash, hives, itching, fever, or wheezing
  • tremors

Less common

  • dizziness
  • increased sweating
  • nausea or vomiting
  • unusual tiredness or weakness

Rare

  • fever
  • severe abdominal or stomach cramps and pain
  • watery and severe diarrhea, which may also be bloody (these side effects may also occur up to several weeks after you stop receiving this medicine)

Other side effects

Some side effects of cilastatin / imipenem may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • diarrhea
  • nausea and vomiting

For healthcare professionals

Applies to cilastatin / imipenem: injectable powder for injection, intramuscular powder for injection, intravenous powder for injection.

Local

Gastrointestinal

Drug-related nausea and/or vomiting appeared to occur more often in granulocytopenic patients than in nongranulocytopenic patients.[Ref]

Dermatologic

Beta-lactams:

Hematologic

Hepatic

Other

Nervous system

Cardiovascular

Psychiatric

Renal

Genitourinary

Hypersensitivity

Beta-lactams:

Respiratory

Musculoskeletal

References

1. (2002) "Product Information. Primaxin (imipenem)." Merck & Co., Inc

2. Embil JM, Soto NE, Melnick DA (2006) "A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus." Clin Ther, 28, p. 1164-74

3. Zhanel GG, Wiebe R, Dilay L, et al. (2007) "Comparative Review of the Carbapenems." Drugs, 67, p. 1027-1052

4. Calandra GB, Hesney M, Grad C (1984) "A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam." Eur J Clin Microbiol, 3, p. 478-87

5. Wang C, Calandra GB, Aziz MA, Brown KR (1985) "Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience." Rev Infect Dis, 7, s528-36

6. Lyon JA (1985) "Imipenem/cilastatin: the first carbapenem antibiotic." Drug Intell Clin Pharm, 19, p. 894-8

7. Calandra GB, Brown KR, Grad LC, et al. (1985) "Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin." Am J Med, 78, p. 73-8

8. Young K (1986) "Imipenem/cilastatin." Pharm Ther Forum, 34, p. 1-3

9. Clissold SP, Todd PA, Campoli-Richards DM (1987) "Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy." Drugs, 33, p. 185-241

10. Patel SA, Braun HL, Fine MS, et al. (1989) "Imipenem-associated elevation of amylase and lipase." Am J Gastroenterol, 84, p. 80-1

11. Schmitt DV, Leitner E, Welte T, Lode H (2006) "Piperacillin/Tazobactam vs Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia-a Double Blind Prospective Multicentre Study." Infection, 34, p. 127-34

12. Rivera M, Crespo M, Teruel JL, Marcen R, Ortuno J (1999) "Neurotoxicity due to imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis." Nephrol Dial Transplant, 14, p. 258-9

13. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I (2008) "Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study." Crit Care Med, 36, p. 1089-96

14. Larsen JW, Gabel-Hughes K, Kreter B (1992) "Efficacy and tolerability of imipenem-cilastatin versus clindamycin + gentamicin for serious pelvic infections." Clin Ther, 14, p. 90-6

15. Semel JD, Allen N (1991) "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J, 84, p. 465-8

16. Zazgornik J, Schein W, Heimberger K, et al. (1986) "Potentiation of neurotoxic side effects by coadministration of imipenem to cyclosporine therapy in a kidney transplant recipient: synergism of side effects or drug." Clin Nephrol, 26, p. 265-6

17. Eng RH, Munsif AN, Yangco BG, et al. (1989) "Seizure propensity with imipenem." Arch Intern Med, 149, p. 1881-3

18. Job ML, Dretler RH (1990) "Seizure activity with imipenem therapy: incidence and risk factors." DICP, 24, p. 467-9

19. Duque A, Altimiras J, Garcia-Cases C, Vidal P (1991) "Vertigo caused by intravenous imipenem/cilastatin." DICP, 25, p. 1009

20. Leo RJ, Ballow CH (1991) "Seizure activity associated with imipenem use: clinical case reports and review of the literature." DICP, 25, p. 351-4

21. Oriordan J, Javed M, Doherty C, Hutchinson M (1994) "Worsening of myasthenia gravis on treatment with imipenem/cilastatin." J Neurol Neurosurg Psychiatry, 57, p. 383

22. Lane M, Kania D, Rapp RP (1996) "Seizures related to use of imipenem-cilastatin." Am J Health Syst Pharm, 53, p. 1605-6

23. Guglielmo BJ, Jacobs RA (1996) "Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin." Am J Health Syst Pharm, 53, p. 2097-8

24. Guglielmo BJ, Jacobs RA (1996) "Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin." Am J Health Syst Pharm, 53, p. 1097-8

25. Frucht S, Eidelberg D (1997) "Imipenem-induced myoclonus." Mov Disord, 12, p. 621-2

26. Campise M (1998) "Neurological complication during imipenem/cilastatin therapy in uraemic patients." Nephrol Dialysis Transplant, 13, p. 1895-6

27. Roberts JA, Lipman J (2006) "Antibacterial Dosing in Intensive Care : Pharmacokinetics, Degree of Disease and Pharmacodynamics of Sepsis." Clin Pharmacokinet, 45, p. 755-773

28. Hantson P, de Coninck B, Horn JL, Mahieu P (1991) "Immediate hypersensitivity to aztreonam and imipenem." Br Med J, 302, p. 294-5

29. Pleasants RA, Walker TR, Samuelson WM (1994) "Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis." Chest, 106, p. 1124-8

30. Romano A, Viola M, Gueant-Rodriguez RM, Gaeta F, Pettinato R, Gueant JL (2006) "Imipenem in patients with immediate hypersensitivity to penicillins." N Engl J Med, 354, p. 2835-7

Further information

Cilastatin/imipenem side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.